The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

被引：120

作者：

Greene, Stephen J. ^{[1
]}

Gheorghiade, Mihai ^{[1
]}

Borlaug, Barry A. ^{[2
]}

Pieske, Burkert ^{[3
]}

Vaduganathan, Muthiah ^{[4
]}

Burnett, John C., Jr. ^{[2
]}

Roessig, Lothar ^{[5
]}

Stasch, Johannes-Peter ^{[6
]}

Solomon, Scott D. ^{[7
]}

Paulus, Walter J. ^{[8
]}

Butler, Javed ^{[9
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA

[2] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN USA

[3] Med Univ Graz, Dept Cardiol, Graz, Austria

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA

[5] Bayer Pharma AG, Berlin, Germany

[6] Bayer HealthCare, Cardiol Res, Wuppertal, Germany

[7] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[8] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Physiol, Inst Cardiovasc Res VU, Amsterdam, Netherlands

[9] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA

来源：

JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2013年 / 2卷 / 06期

关键词：

cGMP; heart failure; phosphodiesterase; 5; preserved ejection fraction; soluble guanylate cyclase; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE SYNTHASE; IMPROVES EXERCISE CAPACITY; PULMONARY-HYPERTENSION; NATRIURETIC PEPTIDE; PHOSPHODIESTERASE-5; INHIBITION; DIASTOLIC DISTENSIBILITY; ENDOTHELIAL DYSFUNCTION; SODIUM-NITROPRUSSIDE; CONTRACTILE RESPONSE;

D O I：

10.1161/JAHA.113.000536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：11

共 50 条

[21] Left Ventricular Stiffening as Therapeutic Target for Heart Failure With Preserved Ejection Fraction
Sakata, Yasushi
Ohtani, Tomohito
Takeda, Yasuharu
Yamamoto, Kazuhiro
Mano, Toshiaki
CIRCULATION JOURNAL, 2013, 77 (04) : 886 - 892
[22] Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction
Zhang, Min
Shu, Hongyang
Chen, Chen
He, Zuowen
Zhou, Zhou
Wang, Dao Wen
BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
[23] Understanding heart failure with preserved ejection fraction: where are we today?
van Heerebeek, L.
Paulus, W. J.
NETHERLANDS HEART JOURNAL, 2016, 24 (04) : 227 - 236
[24] Treatment of Heart Failure with Preserved Ejection Fraction
Barnes, Megan M.
Dorsch, Michael P.
Hummel, Scott L.
Koelling, Todd M.
Bleske, Barry E.
PHARMACOTHERAPY, 2011, 31 (03): : 312 - 331
[25] Targets for Heart Failure With Preserved Ejection Fraction
Nanayakkara, S.
Kaye, D. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 228 - 237
[26] Epidemiology of heart failure with preserved ejection fraction
Dunlay, Shannon M.
Roger, Veronique L.
Redfield, Margaret M.
NATURE REVIEWS CARDIOLOGY, 2017, 14 (10) : 591 - 602
[27] Breakthrough in heart failure with preserved ejection fraction: are we there yet?
Lim, Shir Lynn
Lam, Carolyn Su Ping
KOREAN JOURNAL OF INTERNAL MEDICINE, 2016, 31 (01) : 1 - 14
[28] Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
Borlaug, Barry A.
CIRCULATION JOURNAL, 2014, 78 (01) : 20 - 32
[29] Heart Failure With Preserved Ejection Fraction Time for a New Approach?
Desai, Akshay S.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (04) : 272 - 274
[30] Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction
Hicklin, Harry E.
Gilbert, Olivia N.
Ye, Fan
Brooks, Jeremy E.
Upadhya, Bharathi
CURRENT HYPERTENSION REPORTS, 2020, 22 (10)

← 1 2 3 4 5 →